ECE2022 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (202 abstracts)
Association between clinical and genetic factors and glycemic and weight loss response to liraglutide in patients with type 2 diabetes
Artemis Kyriakidou 1 , Angeliki V. Kyriazou 1 , Theocharis Koufakis 1 , Yiannis Vasilopoulos 2 , Maria Grammatiki 1 , Eirini Mellidou 1 , PANTELITSA RAKITZI 1 , Georgios Karaliolios 1 , Dimitrios Goulis 3 , Pantelis Zebekakis 1 & Kalliopi Kotsa 1
1AHEPA University Hospital, Division of Endocrinology and Metabolism - Diabetes Center, 1st Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2University of Patras, Department of Biology, Section of Genetics, Cell Biology and Development, Patras, Greece; 3Medical School, Aristotle University of Thessaloniki, Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Thessaloniki, Greece
Background: Previous research suggests an association between specific genetic variations and interindividual variability in response to treatment with glucagon-like receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus (T2DM). We aimed to evaluate the role of CTRB1/2 rs7202877 (T>G) polymorphism in glycemic control and weight loss response to liraglutide among Greek patients with T2DM and to identify clinical factors related to prediction of response to liraglutide administration.
Methods: The medical records of 116 adults with T2DM [51% female, mean Body Mass Index (BMI) 35.4±6.4 kg/m2], who had been on treatment with liraglutide for at least 6 months and were genotyped for CTRB1/2 rs7202877 (T>G) polymorphism, using real-time PCR, were evaluated. Clinical and laboratory parameters were measured at baseline, 3 and 6 months after initiation of liraglutide treatment. The good glycemic response was defined as one of the following: i) achievement of glycated hemoglobin (HbA1c) <7%, either at 3 or 6 months after treatment initiation ii) reduction of the baseline HbA1c by ≥1% after 3 or 6 months of liraglutide use, and iii) maintenance of HbA1c <7% that a patient had before switching to liraglutide, after 3 or 6 months of treatment. Weight loss responders were defined as subjects who lost ≥3% of their baseline weight after 3 or 6 months of liraglutide administration.
Results: 97 (84%) patients were homozygous for the wild type rs7202877 T allele (TT) and 19 (16%) patients carried one polymorphic G allele (TG). 81 (70%) and 77 (66%) individuals were classified as glycemic control and weight loss responders, respectively. Heterozygotes had similar responses to liraglutide treatment in terms of glycemic control [odds ratio (OR): 1.25, 95% confidence interval (CI): 0.4, 3.8, P=0.69] and weight loss (OR: 1.12, 95% CI: 0.4, 3.2, P=0.84). In the multivariable analysis, higher baseline HbA1c (adjusted OR: 1.45, 95% CI: 1.05, 2.1, P=0.04) and lower baseline weight (adjusted OR: 0.97, 95% CI: 0.94, 0.99, P=0.01) were associated with better glycemic response to liraglutide, while higher baseline weight was associated with worse weight response (adjusted OR: 0.97, 95% CI: 0.95, 0.99, P=0.02). Both glycemic responders and non-responders demonstrated a significant reduction in weight and BMI from baseline to 6 months (P<0.0001). Both weight responders and non-responders significantly reduced HbA1c after administration of liraglutide (P<0.0001 and P=0.008, respectively).
Conclusion: Specific patient features can predict glycemic and weight loss response to liraglutide in patients with T2DM.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more